Currently, there have been five registered active clinical trials investigating the targeting of BET family proteins, such as RVX-208, I-BET 762, OTX 015, CPI-0610 and TEN-010, in which OTX 015 has reported encouraging results in treating hematologic malignancies [16-19]. The gene discussed is DNER; the disease is hematologic disorder.